Arlt Martin F, Xu Bo, Durkin Sandra G, Casper Anne M, Kastan Michael B, Glover Thomas W
Department of Human Genetics, 4909 Buhl, Box 0618, 1241 E. Catherine Street, University of Michigan, Ann Arbor, MI 48109-0618, USA.
Mol Cell Biol. 2004 Aug;24(15):6701-9. doi: 10.1128/MCB.24.15.6701-6709.2004.
Common fragile sites are loci that form chromosome gaps or breaks when DNA synthesis is partially inhibited. Fragile sites are prone to deletions, translocations, and other rearrangements that can cause the inactivation of associated tumor suppressor genes in cancer cells. It was previously shown that ATR is critical to fragile-site stability and that ATR-deficient cells have greatly elevated fragile-site expression (A. M. Casper, P. Nghiem, M. F. Arlt, and T. W. Glover, Cell 111:779-789, 2002). Here we demonstrate that mouse and human cells deficient for BRCA1, due to mutation or knockdown by RNA interference, also have elevated fragile-site expression. We further show that BRCA1 functions in the induction of the G(2)/M checkpoint after aphidicolin-induced replication stalling and that this checkpoint function is involved in fragile-site stability. These data indicate that BRCA1 is important in fragile-site stability and that fragile sites are recognized by the G(2)/M checkpoint pathway, in which BRCA1 plays a key role. Furthermore, they suggest that mutations in BRCA1 or interacting proteins could lead to rearrangements at fragile sites in cancer cells.
常见脆性位点是在DNA合成受到部分抑制时形成染色体间隙或断裂的基因座。脆性位点易于发生缺失、易位及其他重排,这些重排可导致癌细胞中相关肿瘤抑制基因失活。先前研究表明,ATR对脆性位点的稳定性至关重要,且ATR缺陷型细胞的脆性位点表达大幅升高(A.M.卡斯珀、P.恩吉姆、M.F.阿尔特、T.W.格洛弗,《细胞》111:779 - 789,2002年)。在此我们证明,由于突变或RNA干扰敲低导致BRCA1缺陷的小鼠和人类细胞,其脆性位点表达也会升高。我们进一步表明,BRCA1在阿非科林诱导的复制停滞后G(2)/M期检查点的诱导中发挥作用,且该检查点功能与脆性位点稳定性有关。这些数据表明,BRCA1在脆性位点稳定性中起重要作用,且脆性位点由G(2)/M期检查点途径识别,其中BRCA1起关键作用。此外,这些数据还表明,BRCA1或相互作用蛋白的突变可能导致癌细胞中脆性位点的重排。